miglyol 840: a propylene glycol diester of saturated vegetable fatty acids (C8-C10 chain lengths) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 53471835 |
| MeSH ID | M0213022 |
| Synonym |
|---|
| 77466-09-2 |
| miglyol 840 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The importance of using both pharmacokinetic and efficacy end points to distinguish between formulations is discussed." | ( Effect of formulation on the pharmacokinetics and efficacy of doramectin. Davison, E; Gibson, SP; Kaye, B; Lewis, D; Smith, DG; Weatherley, AJ; Wicks, SR, 1993) | 0.29 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, due to ALA's high polarity its dermal bioavailability is rather limited and thus, permeation enhancement of this active is of major interest in research." | ( Rheological characterization and permeation behavior of poloxamer 407-based systems containing 5-aminolevulinic acid for potential application in photodynamic therapy. Müller-Goymann, CC; van Hemelrijck, C, 2012) | 0.38 |
| " Attempts have been made to evaluate IDE NLCs for its pharmacokinetic and pharmacodynamic profile through the objective of enhancement in bioavailability and effectivity of drug." | ( Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain. Bhatia, MS; Bhatia, NM; Salunkhe, SS, 2016) | 0.43 |
| "IDE lipid-based nanostructured carriers could have potential for efficient drug delivery to brain with enhancement in bioavailability of drug over the conventional formulations." | ( Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain. Bhatia, MS; Bhatia, NM; Salunkhe, SS, 2016) | 0.43 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " This approach led to the identification of formulations based upon sesame oil and ethyl oleate which gave more prolonged doramectin plasma concentrations with no loss in therapeutic efficacy and improved persistent efficacy following subcutaneous administration to cattle at a dosage of 200 micrograms kg-1." | ( Effect of formulation on the pharmacokinetics and efficacy of doramectin. Davison, E; Gibson, SP; Kaye, B; Lewis, D; Smith, DG; Weatherley, AJ; Wicks, SR, 1993) | 0.29 |
| " These types of topical dosage forms could give sustained delivery of drug onto the skin, could tolerate the incorporation of an enhancer, a humectant and an occlusive phase, so they are interesting promises to improve skin absorption of nonsteroidal anti-inflammatory drugs and to prevent side effects associated." | ( Release study of diclofenac from new carbomer gels. Bregni, C; Carlucci, A; Chiappetta, D; Faiden, N; García, R; Pasquali, R, 2008) | 0.35 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (39.22) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||